https://www.selleckchem.com/products/hs-173.html
Trials of BCG vaccination to prevent or reduce severity of COVID-19 are taking place in adults, some of whom have been previously vaccinated, but evidence of the beneficial, non-specific effects of BCG come largely from data on mortality in infants and young children, and from in-vitro and animal studies, after a first BCG vaccination. We assess all-cause mortality following a large BCG revaccination trial in Malawi. The Karonga Prevention trial was a population-based, double-blind, randomised controlled in Karonga District, northern Mal
Like
Comment
Share
